Business Context and Reporting Period
This Form 8-K was filed by TradeUP Acquisition Corp. on June 23, 2023, reporting an event occurring June 22, 2023. The requested company name is Estrella Immunopharma, Inc., but the filing identifies TradeUP Acquisition Corp. as the registrant.
TradeUP Acquisition Corp. was a special purpose acquisition company with units, common stock, and warrants listed on Nasdaq.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Material Changes Versus the Prior Comparable Period
- Nasdaq granted the Company an extension through October 16, 2023 to regain compliance with Nasdaq Listing Rule 5550(a)(3), the Public Holder Rule.
- The Company had previously received notice that it did not satisfy the Public Holder Rule and submitted a compliance plan to Nasdaq on June 5, 2023.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The principal contingency is the Company’s need to regain compliance with the Public Holder Rule by October 16, 2023. Failure to do so could result in further Nasdaq action, including potential suspension or delisting, subject to applicable procedures and appeal rights. The filing provides no operating guidance or management forecast.
Important Facts to Verify
- Confirm whether this filing relates to TradeUP Acquisition Corp. or its proposed successor or business combination entity, Estrella Immunopharma, Inc.
- Verify the Company’s compliance status with Nasdaq as of the October 16, 2023 deadline.
- Review subsequent SEC filings for any delisting notice, compliance determination, business combination developments, or changes to the Company’s securities.
- Confirm the number of public holders and the specific remediation steps included in the June 5, 2023 compliance plan.